Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping
3 other identifiers
observational
269
1 country
2
Brief Summary
We hypothesize that a peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable, stage of their disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2010
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedFirst Submitted
Initial submission to the registry
June 25, 2010
CompletedFirst Posted
Study publicly available on registry
June 28, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2013
CompletedSeptember 9, 2015
June 1, 2010
2.8 years
June 25, 2010
September 8, 2015
Conditions
Study Arms (1)
Sporadic (idiopathic) or familial interstitial pneumonia
We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).
Eligibility Criteria
We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family).
You may qualify if:
- Sporadic cases of Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias.
- Family members ( with or without clinical disease) with a family history of pulmonary fibrosis.
You may not qualify if:
- None.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Duke Universitylead
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
- National Jewish Healthcollaborator
- Vanderbilt Universitycollaborator
Study Sites (2)
National Jewish Health
Denver, Colorado, 80206, United States
Duke University Medical Center
Durham, North Carolina, 27710, United States
Biospecimen
Tubes of blood will be drawn from the subject to extract RNA and DNA for laboratory purposes. Lung biopsy tissue (pathology slides) may be requested for specimen processing. Also Bronchoscopy fluid may be requested.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark P Steele, MD
Duke University
- PRINCIPAL INVESTIGATOR
David A Schwartz, MD
National Jewish Health
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 25, 2010
First Posted
June 28, 2010
Study Start
April 1, 2010
Primary Completion
February 1, 2013
Study Completion
February 1, 2013
Last Updated
September 9, 2015
Record last verified: 2010-06